Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Research
Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Experimental Therapeutics, Molecular Targets, and Chemical Biology

Enhanced Antitumor Activity of T Cells Engineered to Express T-Cell Receptors with a Second Disulfide Bond

Cyrille J. Cohen, Yong F. Li, Mona El-Gamil, Paul F. Robbins, Steven A. Rosenberg and Richard A. Morgan
Cyrille J. Cohen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yong F. Li
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mona El-Gamil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul F. Robbins
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven A. Rosenberg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard A. Morgan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/0008-5472.CAN-06-3986 Published April 2007
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    TCR modification and function. A, schematic representation of the cysteine-modified TCR chains. The numbers indicate amino acid position according to the Immunogenetics database ( 18). EX, extracellular region; TM, transmembrane region; CY, cytoplasmic regions. Hα or Hβ, sequence of the wild-type TCR constant region; Hα-Cys or Hβ-Cys show where the cysteine residue was inserted. B, human PBLs were electroporated with 1G4 or 1G4-Cys and cocultured with HLA-A2+/NY-ESO-1+ cell lines (A375, 397/A2, 624.38, 1359/A2, and 1300) and with the control cell lines 526 (HLA-A2+/NY-ESO-1−) and 1359 (HLA-A2−/NY-ESO-1+). Twenty-four hours after the beginning of the coculture, the concentration of cytokine secreted in the medium (IFN-γ), normalized to the amount of mRNA used, was measured using an ELISA procedure. The difference between 1G4 and 1G4-Cys, based on seven independent experiments, was found to be statistically significant (P = 0.01).

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Expression and function of the cysteine-modified anti-MART-1 TCR F4. A and B, comparison of the surface expression of the wild-type F4 and its cysteine-modified F4-Cys. OKT3-stimulated PBLs were electroporated with mRNA encoding different combinations of F4-TCR chains: F4, F4-Cys, the α chain of the wild-type F4 + the β chain of F4-Cys (noted as F4 α/β Cys), or the opposite noted as F4 α Cys /β. Twenty-four hours after electroporation, we assessed MART-1 tetramer (A) and Vβ12 (B) binding. Percentage of positive cells and the relative MFI (in brackets). The difference of TCR surface expression, based on 13 independent experiments done with 10 different donors, was found to be statistically significant (P < 0.001). C, recognition of tumor lines. Human PBLs were electroporated with the F4 (white), F4-Cys (black), the α chain of the wild-type F4 + the β chain of F4-Cys (noted as F4 α/β Cys; horizontal hatching), or the opposite noted as F4 α Cys /β (diagonal hatching). The electroporated cells (1 × 105) were cocultured with the HLA-A2+ 526 and 624 and the HLA-A2− 888 and 938 melanoma cell lines (1 × 105). Twenty-four hours after the beginning of the coculture, the concentration of IFN-γ and GM-CSF secreted in the medium were measured using an ELISA procedure. This was observed in independent experiments for 10 different donors, and the difference between F4 and F4-Cys was found to be statistically significant (P < 0.001). D, specific killing of tumor cell lines. CD8+ purified human PBLs expressing F4 (♦), F4-Cys (▪), or mock electroporated (○) were cocultured for 3 h with the indicated tumor cell lines previously labeled with 51Cr. Specific lysis was measured at the effector/target (E/T) ratios indicated: (specific release − spontaneous release) / (total release − spontaneous release). We used the following melanoma cell lines: HLA-A2+ (526 and 624) and HLA-A2− (888 and 938) as control lines.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Enhanced properties of different cysteine-modified TCRs. A, purified CD8+ or CD4+ human PBLs (>98% purity) were electroporated with F5 or F5-Cys. Twenty-four hours after electroporation, we assessed MART-1 tetramer binding. Percentage of positive cells and the relative MFI (in brackets). B, electroporated cells were cocultured with melanoma cell lines (HLA-A2+: 526 and 624 and control HLA-A2−: 888 and 938). Twenty-four hours after the beginning of the coculture, the concentration of IFN-γ secreted in the medium was measured using an ELISA procedure. The difference between F5 and F5-Cys, based on 10 independent experiments, was found to be statistically significant (P < 0.001). C, human PBLs were electroporated with different p53-specific TCR: the humanized p53-H, cysteine-modified humanized p53-Hcys, wild-type (fully murine) p53-M, and cysteine-modified murine p53-Mcys. Twenty-four hours after electroporation, we assessed p53 pentamer binding. Percentage of positive cells and the relative MFI (in brackets). D, electroporated cells were cocultured with the tumors p53+/HLA-A2+ (H2087, MDA-MB-231, and Saos-2/*143) and the p53−/HLA-A2+ (Saos-2) cell lines ( 3). Twenty-four hours after the beginning of the coculture, the concentration of IFN-γ secreted in the medium was determined by ELISA. The difference between p53-H and p53-HCys, based on five independent experiments, was found to be statistically significant (P < 0.001).

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    Efficient and preferential pairing of cysteine-modified TCRs. A, TCR titration. OKT3-stimulated PBLs, electroporated with different amount of mRNA (0.2, 0.6, 2, and 6 μg total) encoding either the wild-type receptor F5 or its cysteine-modified version F5-Cys, were cocultured with the melanoma tumor 526. Twenty-four hours after the beginning of the coculture, the concentration of IFN-γ secreted in the medium was measured using an ELISA procedure. B, TCR competition assay. TCR-deficient Jurkat/RT3-T3.5 cells were electroporated with 1 μg of each chain of F4 (white) or F4-Cys (black) along with 1 μg of each chain of the competitor TCR: 1G4, TE-8 (an NY-ESO-1 class I–restricted TCR), and p53-H [for p53-H, we also used an additional amount (i.e., 0.5 μg) indicated as p53-H (1:0.5)]. Twenty-four hours after electroporation, the cells were stained with MART-1 tetramer, and the percentage of MART-1 TCR relative expression was calculated by dividing percentage of tetramer-positive cells of a given sample by that of the control sample (without competitor TCR). All the differences were found to be statistically significant based on Student's t test (P < 0.001).

PreviousNext
Back to top
Cancer Research: 67 (8)
April 2007
Volume 67, Issue 8
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Enhanced Antitumor Activity of T Cells Engineered to Express T-Cell Receptors with a Second Disulfide Bond
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Enhanced Antitumor Activity of T Cells Engineered to Express T-Cell Receptors with a Second Disulfide Bond
Cyrille J. Cohen, Yong F. Li, Mona El-Gamil, Paul F. Robbins, Steven A. Rosenberg and Richard A. Morgan
Cancer Res April 15 2007 (67) (8) 3898-3903; DOI: 10.1158/0008-5472.CAN-06-3986

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Enhanced Antitumor Activity of T Cells Engineered to Express T-Cell Receptors with a Second Disulfide Bond
Cyrille J. Cohen, Yong F. Li, Mona El-Gamil, Paul F. Robbins, Steven A. Rosenberg and Richard A. Morgan
Cancer Res April 15 2007 (67) (8) 3898-3903; DOI: 10.1158/0008-5472.CAN-06-3986
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results and Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Imatinib Sensitizes Bcr-Abl+ Cells to Cisplatin
  • Loss of S1P Lyase Upregulates Bcl-2
  • MBP-1 Inhibits Breast Cancer Metastasis
Show more Experimental Therapeutics, Molecular Targets, and Chemical Biology
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement